These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 15386651)

  • 1. The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.
    Danzon PM; Wang YR; Wang L
    Health Econ; 2005 Mar; 14(3):269-92. PubMed ID: 15386651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of regulation on drug launch and pricing in interdependent markets.
    Danzon PM; Epstein AJ
    Adv Health Econ Health Serv Res; 2012; 23():35-71. PubMed ID: 23156660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A game theoretic model of drug launch in India.
    Bhaduri S; Ray AS
    Health Econ Policy Law; 2006 Jan; 1(Pt 1):23-39. PubMed ID: 18634701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External referencing and pharmaceutical price negotiation.
    Garcia Mariñoso B; Jelovac I; Olivella P
    Health Econ; 2011 Jun; 20(6):737-56. PubMed ID: 20577969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the success rates of new drug development in Japan and the lag behind the US.
    Hirai Y; Yamanaka Y; Kusama M; Ishibashi T; Sugiyama Y; Ono S
    Health Policy; 2012 Mar; 104(3):241-6. PubMed ID: 22172246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The quantity and quality of worldwide new drug introductions, 1982-2003.
    Grabowski HG; Wang YR
    Health Aff (Millwood); 2006; 25(2):452-60. PubMed ID: 16522586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the market for tuberculosis drugs in industrialized and developing nations.
    Schwalbe NR; Wells WA; Geaneotes AP; Forcellina A; Lee MG; Dicola L; Ignatius HR; Walker CL; Raafat T; Patel N
    Int J Tuberc Lung Dis; 2008 Oct; 12(10):1173-81. PubMed ID: 18812048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining the production costs of antiretroviral drugs.
    Pinheiro E; Vasan A; Kim JY; Lee E; Guimier JM; Perriens J
    AIDS; 2006 Aug; 20(13):1745-52. PubMed ID: 16931939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical price differences in the EU: investigation from cardiovascular disease drugs.
    Timur A; Picone G
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):251-6. PubMed ID: 19527097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
    Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
    JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Price regulation and relative delays in generic drug adoption.
    Costa-Font J; McGuire A; Varol N
    J Health Econ; 2014 Dec; 38():1-9. PubMed ID: 25200940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks, prices, and positions: A social network analysis of illegal drug trafficking in the world-economy.
    Boivin R
    Int J Drug Policy; 2014 Mar; 25(2):235-43. PubMed ID: 24418633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of pharmaceutical safety-related regulatory actions in Japan: do tradeoffs exist between safer drugs and launch delay?
    Yamada T; Kusama M; Hirai Y; Arnold F; Sugiyama Y; Ono S
    Ann Pharmacother; 2010 Dec; 44(12):1976-85. PubMed ID: 21098757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of proposed price regulations on new patented medicine launches in Canada: a retrospective cohort study.
    Zhang W; Sun H; Guh DP; Grootendorst P; Hollis A; Anis AH
    CMAJ; 2024 May; 196(20):E691-E701. PubMed ID: 38802136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.